Mind Medicine (MindMed) Inc. (DFTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
One World Trade Center
New York, NY 10007
United States of America (the)
Phone
212 220 6633
Website
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
November 15, 2016
| Name | Title | Pay | Year Born |
| Robert Barrow | Chief Executive Officer & Director | 1.05M | 1989 |
| Scott Freeman | Co-Founder & Clinical Advisor | 306,402 | 1957 |
| Brandi L. Roberts | Chief Financial Officer | 619,239 | 1974 |
| Mark R. Sullivan | Chief Legal Officer & Corporate Secretary | 638,607 | 1971 |
| Daniel Rollings Karlin | Chief Medical Officer | 738,733 | 1980 |
| Stephanie Fagan | Chief Corporate Affairs Officer | 0 | N/A |
| Leonard Latchman | Co-Founder | 0 | N/A |
| Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | 0 | N/A |
| Beth Calitri | Vice President of Corporate Communications | 0 | N/A |
| Gitanjali Jain | VP & Head of Investor Relations | 0 | N/A |
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.